Cipla announced that its wholly-owned subsidiary, Medispray Laboratories, has received a voluntary action indicated (VAI) classification from the U.S. Food and Drug Administration (USFDA) for its API manufacturing facility located in Goa.
According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection of the Medispray facility from 14 to 20 January 2025. The inspection concluded with the issuance of one observation in Form 483.In an email communication dated 11 April 2025, which was received by Cipla on 17 April 2025, the USFDA confirmed the VAI classification for the facility.
The official announcement was made on Thursday, 17 April 2025, after market hours.
Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets.
The pharma majors consolidated net profit jumped 48.73% to Rs 1,570.51 crore in Q3 FY25 as against Rs 1,055.90 crore reported in Q3 FY24. Total revenue from operations grew by 7.10% year on year (YoY) to Rs 7,072.97 crore in the quarter ended 31 December 2024.
The counter rose 0.34% to Rs 1,520.65 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app